Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (137)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (250)
  2. Department of Medicine (250)
  3. Solid Tumor Oncology Division (250)
  4. Survivorship Research (250)
  5. Epidemiology and Biostatistics (99)
  6. Biostatistics Service (85)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (3)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (76)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (77)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (250)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Endocrine therapy and related issues in hormone receptor-positive early breast cancer: A roundtable discussion by the breast cancer therapy expert group (BCTEG)
    Journal Article

    Abraham, J.; Caldera, H.; Coleman, R.; Elias, A.; Goetz, M. P.; Kittaneh, M.; Lower, E.; Mahtani, R.; Mamounas, E. T.; Pegram, M.; more...
    Breast Cancer Research and Treatment (2018)

    Fulltext@MSK | Save
  • Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer
    Journal Article

    Traina, T. A.; Miller, K.; Yardley, D. A.; Eakle, J.; Schwartzberg, L. S.; O'Shaughnessy, J.; Gradishar, W.; Schmid, P.; Winer, E.; Kelly, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor-positive breast cancer
    Meeting Abstract

    Krop, I.; Abramson, V.; Colleoni, M.; Traina, T.; Holmes, F.; Estevez, L.; Hart, L.; Awada, A.; Zamagni, C.; Morris, P.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase I/II trial of palbociclib in combination with bicalutamide for the treatment of androgen receptor (AR)+ metastatic breast cancer (MBC)
    Meeting Abstract

    Gucalp, A.; Edelweiss, M.; Patil, S.; Gounder, M. M.; Feigin, K. N.; Corben, A.; Arumov, A.; Traina, T. A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Men with advanced breast cancer (BC): Initial phase (Ph) 2 clinical activity of seviteronel, a selective CYP17-lyase and androgen receptor (AR) inhibitor
    Meeting Abstract

    Elias, A.; Gucalp, A.; Bardia, A.; Resaul, A.; Eisner, J.; Baskin-Bey, E.; Traina, T. A.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
    Meeting Abstract

    Dent, R.; Tan, T.; Kim, S. B.; Traina, T.; McArthur, H.; Im, Y. H.; Creel, T.; Blackwell, K.
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Norton-Simon hypothesis
    Book Section

    Traina, T. A.; Norton, L.
    In Schwab, M. (Eds.) Encyclopedia of Cancer. 4th ed (2017)

    Fulltext@MSK | Save
  • Log-kill hypothesis
    Book Section

    Traina, T. A.; Norton, L.
    In Schwab, M. (Eds.) Encyclopedia of Cancer. 4th ed (2017)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save